Study of Alwextin® Cream in Treating Epidermolysis Bullosa

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Collaborator: Ann & Robert H Lurie Children's Hospital of Chicago
• Treatments: Allantoin

Criteria

Inclusion Criteria:

• history of epidermolysis bullosa

Exclusion Criteria:

• use of any skin product containing allantoin for 30 days prior to enrollment